NOVKAN — Novakand Pharma AB Share News
0.000.00%
Last trade - 00:00- SEK5.40m
- -SEK10.67m
Brief: Kancera Appoints Peter Selin As New CEO
Brief: Kancera Q1 Operating Loss Widens To SEK 17.2 Mln
Brief: Kancera Announces Process Patent Protection In Japan
Brief: Kancera Q4 Operating Loss Widens To SEK 14.0 Mln
Brief: Kancera Gets Application Approval To Start Kandova Study
Brief: Kancera Reports Promising Preclinical Results From Studies Of Its Fractalkine Axis Blocking Drug Candidates
Brief: Kancera Decides On Rights Issue Of Units And Warrants Of About SEK 90 Mln
Brief: Kancera Initiates Clinical Development Of KAND567 In Ovarian Cancer
Brief: Kancera Q2 Operating Loss Narrows To SEK 15.4 Million
Brief: Kancera Receives Patent Grant In US For The Drug Candidate KAND145
Brief: Kancera Q1 Operating Loss Widens To SEK 11.9 Million
Brief: Kancera Q4 Operating Loss At SEK 12.7 Mln
Brief: Kancera Q3 Operating Loss Widens To SEK 10.9 Mln
Brief: Kancera Reports Top-Line Data From Phase IIa-Study With Kand567 In COVID-19 Patients
Brief: Kancera Share Issue Of About SEK 20.4 Mln Gets Fully Subscribed
Brief: Kancera Provides Update On Development Of Its Pharmaceutical Project And Nominates New Drug Candidate
Brief: Kancera Decides On Directed New Issue And Rights Issue
Brief: Kancera Q4 Oper Loss Widens To SEK 12.9 Mln
Brief: Kancera Q4 Operating Loss Widens To SEK 12.9 Million